Moneycontrol PRO
Open App

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12% Jul 27, 2022 08:22 PM IST

    Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%

    During the current quarter, Dr Reddy’s stands to gain from the receipt of $72 million from the settlement of the Suboxone dispute with Indivior.

  • Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct Jul 13, 2022 07:33 PM IST

    Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct

    Net Sales are expected to increase by 7.7 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs 5,324.7 crore, according to ICICI Direct.

  • Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher Jul 08, 2022 05:14 PM IST

    Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 9,7 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs 5,394.2 crore, according to Prabhudas Lilladher.

  • Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25% Jan 28, 2022 07:17 AM IST

    Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25%

    ICICI Securities expects the India business to grow 10 percent YoY and that in the US by 12.8 percent QoQ led by new launches. It also foresees Russia, CIS & ROW (Rest of World) to show steady growth

  • Dr. Reddy’s Laboratories Q2 PAT may dip 11.5% YoY to Rs 752.2 cr: Prabhudas Lilladher Oct 06, 2021 05:39 PM IST

    Dr. Reddy’s Laboratories Q2 PAT may dip 11.5% YoY to Rs 752.2 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 4.9 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs 5,153.4 crore, according to Prabhudas Lilladher.

  • Dr. Reddy’s Laboratories Q1 PAT seen up 10.2% YoY to Rs 655.4 cr: KRChoksey Jul 13, 2021 11:37 AM IST

    Dr. Reddy’s Laboratories Q1 PAT seen up 10.2% YoY to Rs 655.4 cr: KRChoksey

    Net Sales are expected to increase by 19.1 percent Y-o-Y (up 10.5 percent Q-o-Q) to Rs 5,270.1 crore, according to KRChoksey.

  • Dr Reddy’s Q1 PAT seen up 5.4% YoY to Rs 626.7 cr: ICICI Direct Jul 12, 2021 07:56 PM IST

    Dr Reddy’s Q1 PAT seen up 5.4% YoY to Rs 626.7 cr: ICICI Direct

    Net Sales are expected to increase by 10.9 percent Y-o-Y (up 3 percent Q-o-Q) to Rs 4,910.8 crore, according to ICICI Direct.

  • Dr Reddy's Labs to announce Q4 numbers today, here's what brokerages expect May 14, 2021 11:38 AM IST

    Dr Reddy's Labs to announce Q4 numbers today, here's what brokerages expect

    The company is expected to report double-digit growth in revenue on the back of the Wockhardt acquisition and good business in India and Europe but a drop in the US sales may dent profitability.

  • Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan Apr 12, 2021 08:42 PM IST

    Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

    Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan.

  • Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus Jan 29, 2021 07:28 AM IST

    Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

    Brokerage firm Kotak Institutional Equities expects the company's US business to increase by $8 mn quarter-on-quarter (QoQ) to $255 mn, led by the launch of Kuvan.

  • Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities Jan 22, 2021 01:02 PM IST

    Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities

    Net Sales are expected to increase by 16.5 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 5,121.8 crore, according to Yash Securities.

  • Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher Jan 18, 2021 11:05 PM IST

    Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

  • Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5% Jul 29, 2020 09:21 AM IST

    Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%

    Sharekhan sees 167 bps increase in EBITDA margin due to cost savings and better revenue performance.

  • Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall Jan 28, 2020 06:49 PM IST

    Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall

    The company has filed 20 formulations across the global markets, with three Abbreviated New Drug Application (ANDAs) in the US. It has filed 20 Drug Master Files (DMFs) across the markets, with three DMFs in the US.

  • Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show Jan 28, 2020 11:37 AM IST

    Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show

    HSBC also maintained buy call on the stock and raised price target to Rs 3,430 (from Rs 3,230 earlier)

  • Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay Oct 14, 2019 03:56 PM IST

    Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay

    Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay.

  • Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher Jul 12, 2019 04:50 PM IST

    Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 2.2 percent Y-o-Y (down 5.2 percent Q-o-Q) to Rs. 3,820.3 crore, according to Prabhudas Lilladher.

  • Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23% May 17, 2019 09:27 AM IST

    Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%

    Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter

  • Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak Apr 17, 2019 03:15 PM IST

    Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak

    Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.

  • Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher Apr 12, 2019 01:00 PM IST

    Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.

  • Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed Feb 04, 2019 12:35 PM IST

    Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed

    While maintaining buy call with a price target at Rs 2,704, Japanese brokerage firm Nomura said company's operating performance was ahead of its expectations.

  • Dr Reddy's Q3 preview: Analysts expect strong profit but moderate revenue growth Feb 01, 2019 08:30 AM IST

    Dr Reddy's Q3 preview: Analysts expect strong profit but moderate revenue growth

    Kotak, which sees 2.4% growth in topline, also forecasts 12% YoY growth for India

  • Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan Jan 18, 2019 03:00 PM IST

    Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan

    Net Sales are expected to increase by 1.9 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs. 3,905 crore, according to Sharekhan.

  • Dr. Reddys Q3 PAT seen up 37.7% YoY to Rs. 416.9 cr: ICICI Direct Jan 11, 2019 05:33 PM IST

    Dr. Reddys Q3 PAT seen up 37.7% YoY to Rs. 416.9 cr: ICICI Direct

    Net Sales are expected to increase by 4.7 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 4,015.2 crore, according to ICICI Direct.

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila Jan 04, 2019 10:45 AM IST

    Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

    For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Sections
ISO 27001 - BSI Assurance Mark